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Epithelial-Specific Methylation Marker
A Potential Plasma Biomarker in Advanced Non-small Cell
Lung Cancer
Chanida Vinayanuwattikun, MD,*† Virote Sriuranpong, MD, PhD,† Suebpong Tanasanvimon, MD,†
Poonchavist Chantranuwat, MD,‡ and Apiwat Mutirangura, MD, PhD§
Background: Under physiological conditions, leukocytes contrib-
ute the majority of circulating DNA in plasma. Therefore, detection
of methylation at the SHP-1 promoter 2 (SHP1P2) in plasma, which
represents epithelial tumor-derived circulating nucleic acids, may
serve as a potential noninvasive biomarker for non-small cell lung
cancer (NSCLC).
Materials and Method: A quantitative polymerase chain reaction-
based assay was used to determine the level of SHP1P2 methylation
in plasma. Blood samples were prospectively collected from 58
patients with advanced NSCLC, 20 patients with early NSCLC, and
52 healthy volunteers.
Results: Most of the healthy volunteers exhibited undetectable
levels of SHP1P2 methylation. In contrast, the pretreatment levels of
SHP1P2 methylation in the patients with NSCLC were readily
detectable, with a median value of 770 pg ml1 (0–26,500 pg
ml1), which was significantly higher than that of the healthy
controls. Furthermore, the patients with advanced NSCLC who
presented baseline levels of SHP1P2 methylation of less than
700 pg ml1 exhibited enhanced median progression-free survival
(5.2 versus 2.6 months, p  0.009) and improved median overall
survival (12.6 versus 7.6 months, p  0.01) compared with patients
who exhibited SHP1P2 methylation levels greater than 700 pg ml1.
From a multivariate analysis, the levels of SHP1P2 methylation
were significantly associated with survival rates in advanced
NSCLC.
Conclusion: Measurement of the level of SHP1P2 methylation in
plasma serves as a potential noninvasive biomarker for the prognos-
tic assessment of patients with lung cancer. This biomarker can be
used to develop risk-adaptive treatments for patients with lung
cancer.
Key Words: SHP-1, Methylation, Biomarker, Lung cancer, Epithe-
lial-specific methylation marker.
(J Thorac Oncol. 2011;6: 1818–1825)
Recent studies have indicated that extracellular, freely cir-culating nucleic acids in plasma and serum (CNAPS) are
a valuable biomarker that can be used to detect the presence
of several diseases, such as cancer, cardiovascular disease,
pulmonary thromboembolism, connective tissue disease, in-
fections, and organ transplantation.1–3 In patients with cancer,
the ideal candidate for a CNAPS biomarker should come
from a unique genetic sequence present in the tumor cells.
For example, the presence of viral genetic material, such as
the Epstein-Barr viral genome, in a tumor tissue or blood
from patients with nasopharyngeal carcinoma is important
because these nucleic acids can be used as prognostic and
treatment-monitoring tools.4–7 Nevertheless, few of these
markers are available, and most of them are limited to a few
viral-associated malignancies.
Investigating the genetic and epigenetic alterations of
CNAPS may also represent a noninvasive tool for detecting
and monitoring the outcome of disease and assessing the
patient’s response to treatment in non-small cell lung cancer
(NSCLC).8–10 Although these markers may exhibit strong
diagnostic and prognostic potential, applying these biomark-
ers to clinical practice has been limited by the variable
prevalence of genetic alterations in these markers, which
ranges from 44 to 63% in the plasma of patients with
NSCLC.8–14 These percentages indicate the importance of
finding a more specific and sensitive biomarker that can
accurately detect and predict the course of lung cancer and
the patient’s response to treatment.
Accordingly, we decided to search for a suitable can-
didate biomarker for NSCLC. Previously, we reported a
unique epithelial-specific epigenetic biomarker in the SHP1
gene, which encodes a nonreceptor protein tyrosine phospha-
tase. The methylation of SHP1 at the promoter 2 (SHP1P2)
region is a tissue-specific methylation event that plays a role
in determining the differential expression of SHP1 between
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epithelial and hematopoietic cells.15 Although the methyl-
ation of SHP1P2 is ubiquitous in all epithelial cells, normal
hematopoietic cells exhibit fully unmethylated SHP1P2.16
The tissue-specific methylation profile of SHP1P2 may serve
as a specific biomarker in CNAPS for epithelial malignancies
because most circulating nucleic acids in humans are derived
from hematopoietic cells.17 Therefore, we assessed the levels
of methylated SHP1P2 in the plasma of patients with NSCLC
to determine whether these biomarkers could be used as
noninvasive diagnostic and prognostic tools. The results of
this study may be extremely useful for physicians diagnosing
and treating lung cancer and other types of cancer.
PATIENTS AND METHODS
Study Population
Patients with NSCLC receiving treatment at the King
Chulalongkorn Memorial Hospital were recruited in this
study. The diagnoses of all the patients with NSCLC had
been confirmed either histologically or cytologically. All the
patients with NSCLC were treated and managed according to
the standard local clinical procedures.
In this study, age- and sex-matched healthy volunteers
served as the control group and were recruited from a com-
munity in Bangkok. No one in the control group exhibited
any significant medical condition (Supplemental Table 3,
http://links.lww.com/JTO/A102).
Written informed consent was obtained from all partic-
ipants. The study was approved by the Ethic Committee of
the Faculty of Medicine, Chulalongkorn University.
Sample Collection and DNA Preparation
Before chemotherapy treatment, blood specimens were
collected in ethylenediaminetetraacetic acid tubes. Subse-
quent blood specimens were collected before the second
cycle of treatment. Plasma was harvested after centrifugation
and stored at 70°C until further analysis. Plasma DNA was
extracted from 0.5 to 2 ml of sampled plasma using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instruction. The level of
circulating DNA was quantitated by quantitative polymerase
chain reaction (PCR). For assessment of methylation, DNA
was treated with sodium bisulfite using the EZ DNA Meth-
ylation-Gold kit (Zymo Research, Orange, CA) according to
the manufacturer’s instruction. Then SHP1P2 methylation
was quantitated by quantitative PCR.
Quantitative Analysis of Circulating DNA Level
Measurement of the level of circulating DNA was
performed through real-time PCR with an ABI Prism 7500
Sequence Detection System with a dual-hybridization probe-
specific sequence for GAPDH (NC_000012). The sequences
of the forward and reverse primers are 5-CTA-CTC-TTT-
CCA-CCC-TCG-GAG-T-3 and 5-TGA-GGC-CCT-GCA-
GCG-TAC-TC-3. The dual-hybridization probe sequence is
TAMRA-5-TTG-GGG-TCC-CAA-CGT-GCG-TCG-3-VIC.
Leukocyte DNA extracted from healthy subjects was used to
generate the standard curve. The experiments were performed in
duplicate. The threshold cycle of the unknown target sample was
obtained with a relative amount of DNA in the experimental
sample. The total level of circulating DNA was calculated using
the following equation: C  Q*VDNA/VPCR*Vext, where C rep-
resents the target concentration in plasma (pg ml1), Q repre-
sents the target quantity (pg), as determined by a sequence
detector in PCR, VDNA represents the total volume of DNA
obtained after extraction, VPCR represents the volume of DNA
used for PCR, and Vext represents the volume of input plasma
used for DNA extraction.
Quantitative Measurement of SHP1P2
Methylation by Methylation-Specific
Primer-Based PCR
Methylation-specific primer-based PCR (MSP-PCR) of
SHP1P2 has been described previously.16 Briefly, a duplex
MSP-PCR of bisulfite-treated DNA with oligonucleotides was
conducted. The methylated primers are 5-TGT-GAA-CGT-
TAT-TAT-AGT-ATA-GCG-3 and 5-CCA-AAT-AAT-ACT-
TCA-CGC-ATA-CG-3. The unmethylated primers are 5-
GTG-AAT-GTT-ATTATA-GTA-TAG-TGT-TTG-G-3 and
5-TTC-ACA-CATACA-AAC-CCA-AAC-AAT-3. The PCR
products for methylated and unmethylated alleles had different
sizes and were electrophoresed, visualized, and measured for
intensity using Phosphorimager and ImageQuant software (GE
Healthcare Life Sciences). The SHP1P2 methylation index (MI)
is the ratio of the intensity of the methylated amplicon divided
by the sum of the measured intensities of both amplicons.
Quantitative Measurement of SHP1P2
Methylation Using Absolute Quantitative
Analysis of Methylated Alleles
To accurately measure the level of SHP1P2 methyl-
ation, we devised a real-time PCR-based assay with dual-
hybridization probes. All SHP-1 bisulfite oligonucleotide
sequences were derived from the GenBank accession number
U47924.1. The SHP-1 bisulfite forward and reverse primer
sequences are 5-GGT-GGA-GGA-GGG-AGA-GAT-GT-3
and 5-AAC-ACA-TAT-ATA-CCT-TAC-ACA-CTC-CAA-
A-3, respectively. Methylation- and nonmethylation-specific
dual-hybridization probe sequences are 5-VIC-ACG-AAC-
CCA-AAC-GAT-CCC-ACG-TAMRA-3 and 5-FAM-CAC-
ATA-CAA-ACC-CAA-ACA-ATC-CCA-CA-TAMRA-3,
respectively. All the PCRs were performed in duplicate. The
PCR products were electrophoresed and visualized with
SYBR Green staining. Absolute quantitative analysis of
methylated alleles (AQAMA) was performed as described
previously.18 The standard curves were generated by mixing
varying proportions of DNA previously characterized as
methylated (HeLa) or unmethylated (leukocyte) before bisul-
fite modification. Quantitative SHP1P2 methylation is deter-
mined using the following equation:
Quatitative SHP1P2  C  Methylation index,
Methylation index  mSHP1P2/(mSHP1P2  uSHP1P2),
where C represents the target concentration in plasma (pg
ml1) and mSHP1P2 and uSHP1P2 represent the methylated
SHP1P2 level and the unmethylated SHP1P2 level, respec-
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tively, by real-time PCR-based assay with a dual-hybridiza-
tion probe.
Statistical Analysis
The Mann-Whitney U test was used to assess the
differences among the nonparametric distributed variables.
Most data were expressed as median values unless otherwise
indicated. The 2 or Fisher’s exact test was used to compare
categorical variables. The Pearson’s correlation was used to
assess the correlation between each variable. The receiver
operator characteristic (ROC) curve analysis was used to
analyze the measurement of the SHP1P2 methylation assays.
The differences in SHP1P2 methylation between the baseline
and follow-up samples were analyzed with the Wilcoxon
matched-pairs signed rank test. The two-sided test, at a
significance level of p less than 0.01, was applied. All
statistical analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL).
For a survival analysis, the Kaplan-Meier method of
estimation was used. Progression-free survival (PFS) was
defined as the time interval between the first day of chemo-
therapy and the day when tumor progression became evident,
whereas overall survival (OS) was defined as the time elapsed
between the beginning of treatment and death. The log-rank
test was used to distinguish between the survival curves. The
Cox proportional hazards regression analysis was used to
estimate univariate and multivariate hazard ratios for both
PFS and OS.
RESULTS
Reliability of AQAMA in Detecting Methylated
SHP1P2
The level of methylation of a target DNA sequence is
usually measured with a semiquantitative technique, such as
MSP-PCR. To accurately determine the methylation level of
target DNA in plasma, where the absolute quantity of nucleic
acids is much less abundant than in cells, we investigated the
potential use of AQAMA-PCR with a dual-hybridization
probe to assess the quantity of methylated sequences in the
plasma. The assay was validated by comparing the measure-
ments obtained from semiquantitative MSP-PCR with those
of the AQAMA-PCR, which was performed using a set of
mixed SHP1P2-methylated samples with known concentra-
tions. Indeed, the dual-hybridization probe technique indi-
cated a near-perfect linearity of known samples, with a
Pearson’s correlation coefficient of r2  0.99, whereas the
MSP-PCR exhibited a value of r2  0.78 (Figure 1).
This finding indicated that AQAMA-PCR was precise
in its detection of SHP1P2 in the plasma. Therefore, we
decided to use AQAMA-PCR to determine the levels of
methylated SHP1P2 in the plasma of study participants.
Various Levels of SHP1P2 Methylation in the
Plasma of Patients with Advanced NSCLC and
Controls
We first determined the level of SHP1P2 methylation in
plasma-derived nucleic acids in a cohort of patients with
advanced NSCLC and sex- and age-matched healthy con-
trols. The characteristics of the cohort group are presented in
Supplementary Table 1 (http://links.lww.com/JTO/A102).
Under the high sensitivity and accuracy of the AQAMA-PCR
method, the levels of SHP1P2 methylation in plasma derived
from the controls were generally undetectable (detectable
range: 0–200 pg ml1 in 20 of 52 [38%] subjects) (Supple-
mentary Table 2, http://links.lww.com/JTO/A102). In con-
trast, the levels of SHP1P2 methylation were readily detect-
able in most of the patients with advanced NSCLC (35/38
[92%]), with a significantly higher and broader range of
methylation levels and a median value of 770 pg ml1
(0–26,500 pg ml1; p  0.001). The various levels of methyl-
ation were independent of age, sex (Supplementary Figures 1
and 2, http://links.lww.com/JTO/A102), and smoking status.
The previously mentioned results were consistent with the vari-
able levels of plasma-derived DNA methylation obtained by
other CNAPS studies conducted in other types of patients with
cancer and in healthy control subjects, which stemmed from the
contribution of circulating DNA by cancer cells.
The possibility of using the level of SHP1P2 meth-
ylation as a diagnostic marker for lung cancer was further
investigated. The area under the ROC curve was 0.93,
which represented a strong discrimination between pa-
tients with advanced NSCLC and healthy controls (95%
confidence interval [CI]: 0.86 – 0.99). The cutoff level of
SHP1P2 methylation at 35 pg ml1 was a suitable level for
distinguishing between the two conditions with 89.5% sensi-
tivity and 90.4% specificity (Supplementary Table 3 and
Figure 3, http://links.lww.com/JTO/A102). Similar results
could be obtained by using SHP1P2 MI with a median
SHP1P2 MI of 17% (range 0–62.6%) in patients with ad-
vanced NSCLC, whereas in the controls, this condition con-
FIGURE 1. Comparisons of the absolute quantitative analy-
sis of methylated alleles (AQAMA) and the conventional
methylation-specific primer-based polymerase chain reaction
(MSP-PCR). The results of AQAMA-PCR (solid line, filled tri-
angle) indicated a near-perfect correlation with the known
concentrations of the mixed samples compared with the
semiquantitative measurement of MSP-PCR (solid line, filled
square).
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tinued to be undetectable. In contrast, the level of total
circulating nucleic acids, which exhibited a significantly
higher level in patients with advanced NSCLC compared
with sex- and age-matched controls, was similar to that of
SHP1P2 methylation. The median values of circulating DNA
levels were 2077 pg ml1 (34–26,955 pg ml1) in healthy
controls and 4512 pg ml1 (1339–49,888 pg ml1) in pa-
tients with advanced NSCLC (p  0.002) (Figure 2). Nev-
ertheless, according to our ROC analysis, the area under the
curve was a modest value of 0.69, which was consistent with
a reduced power of discrimination of total circulating DNA
under these conditions. These results suggest that the deter-
mination of SHP1P2 methylation in circulating DNA repre-
sents a potential cancer biomarker.
Patient Characteristics
To investigate the potential of SHP1P2 methylation as
a potential biomarker of NSCLC, we further analyzed plasma
SHP1P2 methylation in samples obtained from additional
patients with advanced or recurrent NSCLC before receiving
chemotherapy treatment. Plasma from 58 patients with ad-
vanced NSCLC was collected prospectively. The median age
of these patients was 59 years. The majority of the patients
were men (39/58, 67%) and exhibited adenocarcinoma his-
tology (45/58, 76%) (Table 1). All patients received a plati-
num-based chemotherapy regimen, either in combination
(91%) with gemcitabine (36%) or paclitaxel (55%) or as a
single agent (9%), according to their physical status. Five
patients prematurely stopped treatment after one cycle of
chemotherapy (three refused to receive further chemotherapy,
one had progressed, and the fifth one exhibited a severe
hypersensitivity reaction to chemotherapy). All patients were
included in the survival analysis. Data obtained until Decem-
ber 2009 indicated that 46.6% of the patients were alive and
that 10.7% of them did not progress. The median follow-up
time in this study was 7.2 months (range: 0.7–15.0 months).
The median OS was 9.9 months (95% CI: 5.8–14.0 months),
and the median PFS was 3.5 months (95% CI: 2.3–4.7
months). Overall, these treatment results were consistent with
those of other reports on advanced NSCLC.19,20
Plasma SHP1P2 Methylation as a Prognostic
Factor of Survival in Patients with Advanced
NSCLC
The median level of plasma SHP1P2 methylation in
this set of patients with advanced NSCLC was 680 pg ml1
(range: 0–28,000 pg ml1). To exclude the influence of
smoking on the epigenetic modification of DNA sequences,
which has been described previously,21,22 we analyzed the
level of SHP1P2 methylation in the nonsmoking subgroup of
patients with advanced NSCLC compare with that of the
healthy nonsmoking controls. The median level of SHP1P2
methylation was 575 pg ml1 (0–28,349 pg ml1), which
was a significantly higher and broader value than those
obtained from the healthy controls (p  0.001) (Supplemen-
tary Figure 4A, http://links.lww.com/JTO/A102). The levels
of SHP1P2 methylation were not significantly correlated with
other demographic variables, such as sex, age, histology, che-
motherapy regimen, and performance status (data not shown).
In addition to its potential ability to diagnose patients with
advanced NSCLC, we investigated whether SHP1P2 methyl-
ation could be used as a prognostic biomarker. Before treatment,
the ROC curve analysis was used to predict the survival outcome
in patients. At a cutoff level of 700 pg ml1, SHP1P2 methyl-
ation was able to separate the patients into two groups according
to their OS, either above or below the median OS, with a
sensitivity of 68% and a specificity of 70%.
Fifty percent of patients with advanced NSCLC exhib-
ited a baseline plasma SHP1P2 methylation level of 700 pg
ml1. According to our survival analyses, in patients with
advanced NSCLC with baseline plasma SHP1P2 methylation
levels of 700 pg ml1, the PFS was 2.6 months (95% CI:
1.3–3.8), and the OS was 7.6 months (95% CI: 3.5–11.6).
FIGURE 2. The levels of SHP-1 promoter 2 (SHP1P2) methylation demonstrated enhanced diagnostic capability in patients
with advanced non-small cell lung cancer (NSCLC) compared with the levels of total circulating DNA. Pretreatment plasma
samples from 52 healthy controls and 38 patients with advanced NSCLC were collected. Both circulating DNA (panel A) and
SHP1P2 methylation (panel B) in patients with advanced NSCLC were significantly higher than those of healthy controls. The
median circulating DNA levels were 4512 pg ml1(1339–49,888 pg ml1) in patients with advanced NSCLC and 2077 pg
ml1 (34–26,955 pg ml1) in healthy controls (p  0.002). Nevertheless, levels of SHP1P2 methylation in controls were
mostly undetectable, in contrast to the higher and broader range exhibited by patients with advanced NSCLC, with a median
value of 770 pg ml1 (0–26,500 pg ml1) (p  0.001).
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Conversely, for patients with SHP1P2 methylation levels less
than 700 pg ml1, the PFS was 5.2 months (95% CI: 2.7–7.7;
p 0.009), and the OS was 12.6 months (95% CI: 10.7–14.4;
p  0.01) (Figure 3). Moreover, according to the univariate
analysis, the baseline SHP1P2 methylation level was the only
independent prognostic factor for both PFS and OS, with p
0.01 and 0.01, respectively, whereas age, sex, smoking status,
performance status, and number of systemic treatments were
not significant prognostic factors. When multivariate analysis
was used, the level of SHP1P2 methylation at 700 pg ml1
was also observed to be an important prognostic factor.
Levels of SHP1P2 700 pg ml1 exhibited hazard ratios of
1.482 (95% CI: 1.096–2.006) and 2.710 (95% CI: 1.209–
6.581) for disease progression and death, respectively (Table
2). These results indicate that the pretreatment level of
SHP1P2 methylation in plasma is an important prognostic
factor for patients with advanced NSCLC.
The Level of Plasma SHP1P2 Methylation and
the Response to Chemotherapy Treatment
Conventionally, several cycles of chemotherapy are
required before physicians can evaluate the patient’s response
to treatment. Therefore, we decided to determine whether the
levels of SHP1P2 methylation can be used to monitor the
patient’s response to chemotherapy. The level of SHP1P2
methylation in plasma was serially measured before the
second cycle of treatment. A total of 42 follow-up blood
samples were collected. Responses to chemotherapy were
recorded by the treating physicians according to their stan-
dard practices. No significant correlation was observed be-
tween the changes in plasma SHP1P2 methylation levels and
the response of lung cancer to chemotherapy treatment.
Additional analyses indicated that changes in the levels of
SHP1P2 methylation did not correlated with either both PFS
(p  0.133) or OS (p  0.995).
Exploratory Analysis of Plasma SHP1P2
Methylation in Early-Stage NSCLC
To further expand our understanding of the role of plasma
SHP1P2 methylation as a biomarker in NSCLC, an exploratory
cohort of 20 resectable NSCLC cases (Table 3) was investi-
gated. Consistent with the analyses in patients with advanced
NSCLC, the level of SHP1P2 methylation in patients with stages
I–III NSCLC was apparently higher than in healthy controls,
TABLE 1. Demographic Data and Treatments of Patients
with Advanced NSCLC
Characteristics No. of Patients (%)
Patients with NSCLC 58
Age (yr)
Median 59 yr
Range 37–83 yr
Sex
Female 19 (33)
Male 39 (67)
Histology
Adenocarcinoma 45 (76)
Squamous cell carcinoma 6 (11)
Large cell carcinoma 2 (4)
Other 5 (9)
Smoking status
Smoker 33 (57)
Nonsmoker 25 (43)
ECOG performance status
ECOG 0 6 (10)
ECOG 1 47 (81)
ECOG 2 5 (9)
First-line chemotherapy
Paclitaxel/carboplatin 32 (55)
Gemcitabine/carboplatin 21 (36)
Carboplatin 5 (9)
Total regimen of treatment
2 regimen 35 (60)
2 regimen 23 (40)
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group.
FIGURE 3. Levels of plasma SHP-1 promoter 2 (SHP1P2)
methylation were used to predict the survival rates of pa-
tients with advanced non-small cell lung cancer (NSCLC).
The results of the Kaplan-Meier survival curve analysis for
progression-free survival (PFS) (panel A) and overall survival
(OS) (panel B) in patients with advanced NSCLC indicated
that patients with low levels plasma of SHP1P2 methylation
(700 pg ml1 [solid line, filled circle]) had improved PFS
and OS rates compared with those with high levels of
plasma SHP1P2 methylation (700 pg ml1 [solid line, filled
triangle]).
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with a median value of 1249 pg ml1 (358–10,488 pg ml1;
p  0.001). Similar results were obtained with the analyses of
the nonsmoking subgroup of resectable NSCLC compared with
the nonsmoking healthy controls (p  0.001) (Supplementary
Figure 4B, http://links.lww.com/JTO/A102). Interestingly, the
total circulating DNA levels in the plasma measured in these
patients with early-stage NSCLC were not significantly dif-
ferent from those of the controls in a pivotal study. The
median circulating DNA levels were 1885 pg ml1 (376–
17,542 pg ml1) in patients with resectable NSCLC com-
pared with 2077 pg ml1 (34–26,955 pg ml1) in the healthy
controls (p  0.36) (Figure 4). This result indicated that the
level of circulating DNA was a less sensitive and specific
biomarker than SHP1P2 methylation. Accordingly, only lev-
els of SHP1P2 methylation can be used to distinguish patients
with early stages of NSCLC from healthy controls.
DISCUSSION
In many circumstances, the nucleic acids derived from
cancer cells may be the most significant source of
CNAPS.23–25 In patients with internal organ malignancies,
such as lung cancer, in which tumor tissue is generally
difficult to access, the study of CNAPS may provide an
important tool for examining these malignancies and, thus,
may allow us to develop a potentially noninvasive method of
cancer detection or treatment monitoring. In this study, we
have demonstrated that the quantitative evaluation of the
level of tissue-specific epigenetic modifications at the proxi-
mal 5 element of SHP1 in the plasma may serve as a
potential biomarker for the diagnostic and prognostic classi-
fication of lung cancer. The level of SHP1P2 methylation is
significantly elevated in plasma derived from patients at
various stages of NSCLC compared with that of healthy
controls. Moreover, the high pretreatment level of SHP1P2
methylation in CNAPS indicated a significant correlation
with survival outcome and served as an independent prog-
nostic factor for advanced NSCLC. Furthermore, possessing
this information along the level of bulk circulating DNA
might improve the ability of researchers to distinguish be-
tween circulating DNA derived from cancer cells and various
medical conditions that may affect the level of total circulat-
ing DNA.
In investigating biomarkers for lung cancer, several
studies have demonstrated moderate marker sensitivity and
specificity.8–10 Using multiple tumor suppressor genes, in-
cluding p16, death-associated protein kinase, glutathione
S-transferase P1, and the DNA repair gene O6-methylgua-
nine-DNA-methyltransferase, which have been demonstrated
to be crucial in lung cancer pathogenesis, as biomarkers has
indicated an approximately 50% detection rate of aberrant
methylation in CNAPS.9 An additional study using six ge-
netic markers, including the tumor suppressor gene (BLU),
TABLE 2. Results of Survival Analysis Using a Cox-Proportional Hazard Model of Patients with Advanced NSCLC in
Correlation with Clinical Parameters and SHP1P2 Methylation Status
Factors
Univariate Hazard
Ratio of Death
(95% CI) P
Multivariate Hazard
Ratio of Death
(95% CI) P
Univariate Hazard
Ratio of Recurrence
(95% CI) P
Multivariate Hazard
Ratio of Recurrence
(95% CI) P
Sex: male vs. female 1.24 (0.56–2.72) 0.58 0.64 (0.19–2.12) 0.47 1.02 (0.75–1.39) 0.86 0.98 (0.63–1.52) 0.94
Age: 60 vs. 60 yr 1.12 (0.54–2.30) 0.75 1.38 (0.65–2.95) 0.39 1.03 (0.77–1.37) 0.82 1.00 (0.75–1.35) 0.96
Smoking status: yes vs. no 1.52 (0.72–3.21) 0.26 1.98 (0.57–6.84) 0.27 1.00 (0.75–1.33) 0.97 0.99 (0.64–1.52) 0.96
ECOG: 0 or 1 vs.2 0.79 (0.23–2.65) 0.70 0.34 (0.07–1.55) 0.16 0.72 (0.27–1.88) 0.50 0.67 (0.20–2.24) 0.52
Regimen Rx 2 vs. 2 2.58 (1.13–5.91) 0.02 2.8 (1.19–6.58) 0.01 ND ND
SHP1P2 methylation
700 vs. 700 pg ml1
2.36 (1.22–5.64) 0.01a 2.71 (1.20–6.07) 0.01a 1.47 (1.09–1.97) 0.01a 1.48 (1.09–2.00) 0.01a
a Statistical significance.
CI, confidence interval; ND, not determine; NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group.
TABLE 3. Baseline Characteristics of Patients with
Resectable NSCLC
Characteristics No. of Patients (%)
Patients with NSCLC 20
Age (yr)
Median 61 yr
Range 45–83 yr
Sex
Female 4 (20)
Male 16 (80)
Histology
Adenocarcinoma 14 (70)
Squamous cell carcinoma 4 (20)
Large cell carcinoma 1 (5)
Other 1 (5)
Smoking status
Smoker 12 (60)
Nonsmoker 8 (40)
Staging UICC
Stage I 13 (65)
Stage II —
Stage III 7 (35)
Adjuvant chemotherapy
Yes 6 (30)
No 14 (70)
Adjuvant radiation
Yes 4 (20)
No 16 (80)
NSCLC, non-small cell lung cancer; UICC, Union for International Cancer Control.
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the cadherin 13 gene (CDH13), the fragile histidine triad gene
(FHIT), the cell cycle control gene p16, the retinoic acid
receptor  gene (RAR), and the Ras association domain
family 1 gene (RASSF1A), demonstrated a 63% rate of
methylation detection in CNAPS.10 Our current report dem-
onstrated high levels of sensitivity and specificity, with val-
ues of 89.5% and 90.4%, respectively, obtained by measuring
SHP1P2 methylation in plasma to distinguish patients with
lung cancer from healthy controls. The improved results of
this approach may be due to the exclusive nature of methyl-
ation of SHP1P2 in epithelial tissue and not in hematopoietic
cells, which may lead to a higher probability of detection.
Increased levels of SHP1P2 methylation may serve as
an indicator of the tumor burden in peripheral circulation,
which may represent the whole-body tumor load. The in-
creased baseline tumor volume may confer more resistance
and poorer treatment outcomes. Nevertheless, this study
could not demonstrate a convincing correlation of serially
measured levels of SHP1P2 methylation with patients’ out-
comes according to clinical radiographic responses to treat-
ment. One possible explanation for this shortcoming is that
chemotherapy treatment may lead to the release of tumor
DNA into circulation and interfere with the equilibrium of
circulating tumor DNA. Another possibility is that our lim-
ited study population may not provide adequate power for our
analysis. Therefore, a larger cohort would be necessary to
address these issues adequately.
One important characteristic of the controls in this
study is that all of them were nonsmoking. Our comparative
subgroup analyses have shown that the effect of smoking may
not be a critical factor to alter the experimental results.
Nevertheless, as the majority of patients with lung cancer in
general population are current or former smokers, it would be
appropriate to further study the SHP1P2 methylation as the
validation studies using appropriately matched cases and
controls with a smoking history.
Under physiological conditions, circulating nucleic
acid can be detected at a low level and is predominately
contributed from hematopoietic cells.17 Our data demon-
strated that the detection of SHP1P2 methylation in the
plasma of patients with lung cancer with the AQAMA-PCR
method is feasible and has a high sensitivity. One of the most
important factors contributing to our analysis is that SHP1P2
methylation is exclusively found in epithelial cancer cells and
not in hematopoietic cells. It would be interesting to further
investigate the potential applications of using plasma
SHP1P2 methylation as a biomarker for other types of epi-
thelial malignancies.
In conclusion, our study demonstrates the potential uses
of measuring epithelial tissue-specific epigenetic modifica-
tions of SHP1P2 in CNAPS, which may be used to support
the diagnosis and predict the prognosis of patients with
advanced NSCLC.
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FIGURE 4. Plasma levels of SHP1P2 methylation were analyzed in 20 patients with resectable stages I–III non-small cell lung
cancer (NSCLC). The total quantity of circulating DNA (panel A) exhibited no significant difference between patients with
early NSCLC and the healthy controls, with median levels of 1885 pg ml1 (376–17,542 pg ml1) and 2077 pg ml1 (34–
26,955 pg ml1), respectively (p  0.36). In contrast, the levels of SHP1P2 methylation (panel B) were higher and broader in
patients with early stages of NSCLC compared with those of the healthy controls, with median values of 1249 pg ml1 (358–
10,488 pg ml1) and undetectable, respectively (p  0.001).
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